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1. Introduction
Medicinal chemistry is an area that creates important links between the function of living 
organisms and the action of substances, whether natural or synthetic. This includes stud-
ies of structure–activity and dose–response associations in cell culture systems, in vitro and 
subsequent in vivo studies. The treatment of many diseases requires continuous invention, 
synthesis, characterization, and final testing of new designed compounds. Recently, there is 
also growing interest in better and more targeted use of the rich spectrum of effective natu-
ral substances extracted from plants. Each study thus contributes to the characterization of 
the effects of substances in order to achieve the least possible side effects in interactions and 
metabolism but significant expected ones. Also, part of such studies has been carried out at 
our workplace, which show the necessary and complementary role of identifying the effects 
and use of these substances. In this way, we introduce a shortened preview of unregulated 
endogenous production of reactive oxygen and nitrogen species in the biological activity of 
compounds in mitochondria.
2. Reactive oxygen species production in mitochondria
Mitochondria are two membrane organelles present in all cells that have a nucleus. They 
are the energy center of the cells. Their primary role is the production of ATP in oxidative 
phosphorylation, and the basis of the aerobic oxidation is the citric acid cycle interconnection 
representing the final metabolic pathway of oxidation of all major nutrients to the respiratory 
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chain where oxidation of reduced coenzymes results in ATP formation. By the process of 
oxidative phosphorylation, the mitochondria have an irreplaceable function in the forma-
tion of metabolic energy in the form of ATP. The electrodes released in this process from 
reduced substrates are transferred to O
2
 via the H+ pumps of the respiratory chain. Pumps 
(complexes I–IV) form a H+ gradient through the internal mitochondrial membrane, and the 
electrochemical energy of this gradient is then used to synthesize ATP complex V, ATP syn-
thase [1]. Gradual reduction of O
2
 occurs through several interstages when reactive oxygen 
species (ROS) are formed. One-electron reduction of O
2
 to superoxide radical (O
2
˙−) is ther-
modynamically more advantageous, even for substances with relative oxidation ability, so in 
the mitochondria, a number of electron donors potentially allow this reaction [2]. However, 
only a small number of mitochondrial electron transporters with thermodynamic potential 
to reduce O
2
 actually act. In most cases, small-molecule electron transporters such as NADH, 
NADPH, reduced coenzyme (CoQH
2
), and reduced glutathione (GSH) do not react with O
2
 
but regenerate it. Instead, O
2
˙− production takes place on the redox-active prosthetic groups 
of proteins or electron-binding proteins such as CoQH
2
, which is a kinetic factor that allows 
or prevents the reduction of O
2
 molecules and determines the production of O
2
˙− in the mito-
chondria [3]. The mechanism of mitochondrial production and release of H
2
O
2
 and O
2
˙− can 
be seen as described in more detail in [4]. Overall, in aerobic metabolism, the mitochondrial 
oxidative phosphorylation system balances the reduction of O
2
 to H
2
O in maximizing ATP 
synthesis with the simultaneous production of ROS only to the amount required for cell sig-
naling [5].
The major part of the mitochondrial ROS production is formed as a by-product of the res-
piration on the inner side of the inner mitochondrial membrane. Complex IV (cytochrome c 
oxidase), a terminal component of the electron transport chain, receives four electrons from 
cytochrome c and reduces one molecule of O
2
 to two H
2
O. The intermediates remain partially 
reduced until they are completely reduced and are not secreted in measurable amounts [6]. 
Historically, the O
2
˙− producing complex III was described as the first site of ROS produc-
tion—in the Q-cycle [7]. Theoretically, the oxidation of succinate by succinate dehydrogenase 
(complex II, SDH) leads to significant O
2
˙− formation—but so far it has not been measured. 
Thus, it is not entirely clear whether SDH produces in situ mitochondrial ROS. Nevertheless, 
the production of ROS complex II is a significant source in many tissues via the reverse electron 
transport mechanism. This particular phenomenon results from a high membrane potential 
that thermodynamically favors complex II as a donor for complex I., thanks to which succinate 
supports production of ROS in complex I. Thanks to which succinate supports production of 
ROS in complex I [6]. Complex I (NADH dehydrogenase) is the main entry of electrons into 
the respiratory chain. It is a significant source of ROS, namely, O
2
˙− and H
2
O
2
, although it is 
very complicated to find out whether it is the major source of ROS in mitochondria in vivo. All 
evidence of significant ROS production was obtained in in vitro studies [8].
The mitochondria also contain other sources, outside the respiratory chain that highlight 
ROS production. On the outer mitochondrial membrane, there are cytochrome b5 reductase 
and monoamine oxidase. Cytochrome b5 reductase is present in all mammalian tissues and 
is capable of production O
2
˙− at a very high rate of about 300 mmol.min−1.mg of protein−1. 
Monoamine oxidases (MAO-A and MAO-B) are also present in all tissues of mammals. 
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They catalyze the oxidation of biogenic amines while releasing H
2
O
2
 [9]. On the outside 
of the internal mitochondrial membrane, the conversion of dihydroorotate to orotate cata-
lyzes the de novo synthesis of uridine monophosphate dihydroorotate dehydrogenase. It is 
considered to be the source of O
2
˙− and H
2
O
2
, although its ability to produce O
2
˙− requires 
further study. Also, part of a glycerophosphate shuttle, the mitochondrial glycerol-3-phos-
phate dehydrogenase, is present in all cells but with uneven expression and mediating the 
formation of H
2
O
2
 [10]. In the mitochondrial matrix, there is localized aconitase catalyzing 
the conversion of citrate to isocitrate within the Krebs cycle. Enzyme contains a Fe-S cluster 
that can be oxidized by O
2
˙− but also H
2
O
2
 leading to ˙OH production [11]. The subunit of 
lipoamide dehydrogenase from the ketoglutarate dehydrogenase complex, located on the 
inner side of the membrane turned into the mitochondrial matrix, produces O
2
˙− and H
2
O
2
. 
The subunit of the pyruvate dehydrogenase complex, dihydrolipoyl dehydrogenase, is also 
a significant source of ROS [12].
Mitochondria and ROS signaling control cell homeostasis by regulating processes of physi-
ological cell death (apoptosis), including autophagy however also that of survival. Damage 
of mtDNA, protein carbonylation, or lipid peroxidation due to increased ROS production 
have been documented in many studies, and due to the localization and metabolic role of the 
organelles, they can lead to an energy disaster of the cell. Therefore, the production of ROS 
by mitochondria is considered crucial for cell survival or death. Many proteins that mediate 
apoptosis and autophagy directly affect ROS signaling by translocation into the mitochondria 
compartment and subsequent modulation of pro- or antioxidant enzymes [9].
3. Testing compounds
Synthetic and natural substances can affect the production of ROS; alter the redox state of 
the cell and, depending on the extent of the oxidative change; affect proliferation; or induce 
apoptosis. Chalcones are intermediate products of biosynthesis of a wide variety of plant 
polyphenols, flavonoids. Chalcones, as α, β-unsaturated carbonyl compounds have a wide 
range of substituents. The cycles are connected by three strongly electrophilic carbons, and 
the whole system creates a linear or almost planar structure [13]. They also contain a keto-
ethylene group (–CO–CH=CH–). They have conjugated double bonds and a fully delocalized 
π-electron system on both benzene rings [14]. Structure–activity studies have shown that the 
cytotoxicity of chiral analogues is affected by the shape of the molecules [15, 16]. The mul-
timodal pharmacodynamic, structural diversity of synthetic and natural chalcones and the 
constitutive elements that create optimal toxicity vary for each class of chalcones, and there 
are no generally valid rules of relationship between structure and activity [17]. Changes in the 
structure create a high degree of diversity which, as was shown, is useful for the development 
of new drugs with better efficacy, lower toxicity, and good pharmacological action. Thus, 
chalcones have become of interest not only in the academic but also in the industrial sphere 
and are used as intermediates for the preparation of compounds having therapeutic utility. 
They are currently used in the treatment of viral, cardiovascular diseases, parasitic infections, 
pain, inflammation, and gastric cancer, as well as additives and cosmetic ingredients [14]. 
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Some natural but also synthetic chalcones have demonstrated cytotoxic activity against tumor 
cell cultures by inhibiting cell growth. However, they are also effective as anticancer and che-
mopreventive agents in vivo [18–20]. The amount of clinically useful antitumor drugs exhib-
its a genotoxic effect based on their affinity to amino groups of nucleic acid, but chalcones 
exhibit a pronounced affinity to thiols [15]. These reactions can alter intracellular redox (redox 
signaling) that can modulate processes such as DNA synthesis, enzyme activation, selective 
gene expression, and cell cycle regulation [21]. Many of the pharmacological potentials of 
chalcones are not used yet.
Summarizing the current knowledge of chalcone efficiency and their cyclic analogues ((E)-2-
arylmethylene-1-indanone, (E)-2-arylmethylene-1-tetralone, and (E)-2-arylmethylene-benzosuberone) 
with several types of substituents, our studies were then primarily focused on monitoring 
their effects on mitochondria with respect to the production of ROS and the subsequent effects 
on selected antioxidant markers and ATP production. As the primary organ of xenobiotic 
metabolism in the body is the liver, studies with 4′-methyl-, methoxy- [16], 4′-hydroxy- [22], 
and 4′-dimethylamino-cyclic analogues of chalcones [23] were provided on mitochondria 
isolated from the rat liver. Analogues with methyl substituents showed rather a protec-
tive, antioxidant effect. Observed insufficiency in the antioxidant system and the level of 
reduced glutathione and associated enzymes such as glutathione peroxidase and glutathione 
reductase were significantly induced by the presence of benzosuberone in all types of sub-
stituents. They act as uncouplers of mitochondrial respiration, thus reducing ATP production. 
4′-Hydroxy and 4′-dimethylamino analogues of chalcones exhibited similarly toxic effects as 
(E)-2-arylidene-1-indanones. Chalcones with substituents that increase the electron density 
of the B-ring, such as methoxy, butoxy, or dimethylamino groups, do not exhibit significant 
reactivity to reactive species [24].
The current level of knowledge makes it possible to use some of these biological properties of 
chalcone derivatives influenced by the nature of their substitution, such as the ability to inhibit 
12-lipoxygenase and cyclooxygenases with 2′-hydroxychalcones, 4′-hydroxychalcones, and 
2′,4′-dihydroxychalcones. Selective inhibitory effects on arachidonic-induced platelet aggrega-
tion predict them as antithrombotic or anti-inflammatory agents [25]. Under the low pH, the 
amino group, which are conditions normally found in tumors, is in protonated form increasing 
β-carbon electrophilicity in enone linkage, thereby increasing its reactivity as nucleophile accep-
tor in Michael additions [15], for example, thiol groups. Substantial antiproliferative activity 
was observed for chalcones with substituted amino groups [26]. All benzosuberone cyclic ana-
logues at incubation with mitochondria caused a significant decrease in reduced glutathione 
(GSH) levels and simultaneous increase in glutathione peroxidase (GPx) activities. Lowering 
GSH levels most clearly defines the conditions of strong oxidative stress and leads to changes 
in the redox potential of the cell [27]. Although many antioxidant defense systems exist in 
the mitochondria, their maintenance is energy demanding. The first condition is a sufficient 
amount of ATP needed to synthesize low molecular weight antioxidants and molecules that 
provide uptake of ROS and ROS by-products. Benzosuberone as well as indanone analogues 
acted in mitochondria as phosphorylation deactivators, thereby reducing ATP production. GSH 
itself is able to reduce reactive oxygen and nitrogen species (RNOS); however, it is synthesized 
only in cytosol. Although it easily passes through the outer mitochondrial membrane via porin 
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channels, it cannot pass through the inner mitochondrial membrane into the matrix as the 
anion. Here, the 2-oxoglutarate antiport is applied [28]. By importing GSH, mitochondria lose 
an important intermediate of the Krebs cycle, which must be replaced by anaplerotic reactions. 
It is important to note that in experiments, we have been working with isolated mitochondria 
where transfer of de novo synthesized glutathione was not possible. However, the energy inten-
sity to maintain the redox status was not reduced. O
2
˙− produced in the mitochondrial matrix, 
the membrane space, and the outer mitochondrial membrane reacts with other electron accep-
tors such as NO but primarily leads to the production of H
2
O
2
. The local antioxidant capacity of 
peroxidases then determines oxidative damage or H
2
O
2
-mediated signaling. The GPx catalytic 
mechanism requires cyclic oxidation/reduction of cysteine or selenocysteine residues at the 
catalytic center where GSH is used as a cofactor and GSSG is formed. Reactivation through 
glutathione reductase (GR) requires a reduction potential of NADPH, whose production also 
requires energy. The presence of glucose-6-phosphate dehydrogenase (and also isocitrate dehy-
drogenase), a source of NADPH formation in mitochondria, have been proven [29], but the 
enzyme is extremely sensitive to H
2
O
2
 levels, leading to its inhibition [29]. Affection of ATP 
production and changes in GSH levels are associated with the affection of apoptosis, cell divi-
sion, and growth [30]. According to the decrease in mitochondrial membrane potential, they are 
able to incorporate into the membrane and induce apoptosis [31]. Conversely, the reduction of 
ROS production in the mitochondria by partial uncoupling of oxidative phosphorylation, such 
as observed with tetralone analogues, is a protective mechanism and also corresponds to the 
measured values of antioxidant parameters.
4. Conclusion
As a result of our observations, (E)-2-arylidene-1-tetralone shows antioxidant and (E)-2-
arylidene-1-benzosuberone significant pro-oxidant and cytotoxic properties regardless of the 
character of the substituent. The findings have contributed to the targeted synthesis of deriva-
tives that are expected to enhance the effect due to structural modification. The mentioned 
cyclic analogues of chalcones served as a structural substrate, with the aromatic ring B being 
replaced by a ferrocene. In previous studies on various different ferrocene derivatives, some 
have been shown to exhibit surprisingly high toxicity and antiproliferative activity [32–34]. 
Among the unique derivatives available for study, the antiproliferative effect of the (E)-3-
(ferroceneethylene)-4-chromanone was the most effective [35]. The pronounced effect of cell 
viability and colony formation of cancer cells in dose-dependent manner has been shown by 
1,1′-bis[(1-oxoindane-2-ylidene) methyl] ferrocene. The mechanism by which tested ferroce-
nyl compounds could demonstrate these remarkable properties is probably based on their 
activity with RNOS, which subsequently affected the antioxidant mechanisms of mitochon-
dria. In general, the activity of the compounds with respect to ˙OH and nitric oxide (NO) 
was very weak but, however, marked toward O
2
˙− and the peroxynitrite anion (ONO
2
−). 
The 1,1′-bis[(1-oxoindane-2-ylidene) methyl]ferrocene and 1,1′-bis[(1-oxotetralin-2-ylidene)
methyl] ferrocene were involved in the significant production of O
2
˙−, leading to increased 
activities of superoxide dismutase; additionally, 1,1′-bis[(1-oxoindan-2-ylidene)methyl]
ferrocene also exhibited the lowest inhibition of NO and ONO
2
−. In addition to preserved 
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concentrations of GSH, the mechanism of action, especially in this most effective derivative, 
is likely to be the modulation of mitochondrial activity through the induction of nitrosative 
stress.
The demonstration from our workplace suggests a long-term process of characterizing the 
effects of compounds, which contributes only a small amount to their complex knowledge. 
That is why authors have been invited to create the content of this book to bring their work 
and theoretical experiences in this area through their chapters.
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